Sean Stowell, MD
Blood Banking & Transfusion Medicine · Boston, MANPI 1841517240
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Novartis at 40.7% of the total. Reporting peaked in 2022 at $11,760 and has fallen 81.9% since, to $2,131 in 2025.
Across 25 payments — averaging $1120.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$11K
- Grifols Diagnostic Solutions, Inc.$9K
- Cerus Corporation$7K
- Werfen USA LLC$56
- AstraZeneca$36
- Argenx US, Inc.$34
Across 2 payments — averaging $50,410 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$101K
What the payments were for
- Consulting fees$11,40041%
- Speaking & faculty fees$9,50034%
- Travel & lodging$6,17222%
- Food & beverage$9413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 2 | $11,400 |
| Grifols Diagnostic Solutions, Inc. | 16 | $9,053 |
| Cerus Corporation | 4 | $7,434 |
| Werfen USA LLC | 1 | $56 |
| AstraZeneca | 1 | $36 |
| Argenx US, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADAKVEO$11,400
- INTERCEPT BLOOD SYSTEM FOR PLATELETS$7,434
How this compares
Too few blood banking & transfusion medicine providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other blood banking & transfusion medicine in Boston
- Carlo BrugnaraBoston$220K
- Richard M KaufmanBoston$24K
- Li ChaiBoston$511
- Hirotomo NakaharaBoston$225
- William SavageBoston$118
- Karen QuillenBoston$99
- Grace KaoBoston$50
- Leslie SilbersteinBoston$0
- Mark PopovskyBraintree$593K
- Yanhua LiWorcester$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.